Trending...
- Dallas Maestro Jason Davis Sr. Celebrates Prayze Factor Award Victory Unveils Duo Album Release - 284
- California: Governor Newsom takes action to help lower prices amid Trump's nationwide gas and diesel price spike - 145
- California: Governor Newsom signs bills to strengthen accountability for cold storage facilities, following emergency in Boyle Heights - 129
Presentation will highlight this novel vascular disruptive antioxidant agent for treating wet and dry AMD with potential synergy given concurrent therapies
RIVERSIDE, Calif. - Californer -- Citrus Therapeutics, LLC, a manufacturer of innovative therapies and an early leader in novel multi-pharmacophore agents for AMD treatment, will present on its patent-pending therapeutic agent, CTZ1™, at the OIS XII event on December 2nd in San Diego, CA. CTZ1™ is the first-of-its-kind vascular disruptive agent (VDA) for treating both wet and dry AMD and was selected for this most competitive showcase for emerging ophthalmology and retina therapeutics and devices.
Citrus Therapeutics is also considered for the 2022 Ophthalmology Innovator Award for CTZ1™.
CTZ1™ is a unique vascular disruptive agent for combating the oxidative damage encountered in macular degeneration. CTZ1™ combines an antioxidant moiety fused to an angiogenic-modulating activity structure; consequently, this multi-pharmacophore combination mitigates oxidant damage experienced in AMD. CTZ1™ - as a "vascular disruptive agent" - can stabilize and temper pathological angiogenic processes secondary to progressive AMD.
More on The Californer
CTZ1™ is currently being developed with potential as a topical (i.e., eye drop solution) and local (i.e., intravitreal) therapy.
CTZ1™ makes its debut from Citrus Therapeutics, LLC, based out of Riverside, California. Citrus Therapeutics is owned and operated by Eric Chin MD, David Almeida MD MBA PhD, and Mr. Ahmad Alkayali, inventor.
For more information about CTZ1™ and its applications email salkayali@citrustherapeutics.com
About Citrus Therapeutics
Citrus Therapeutics, LLC is a U.S. company based in Riverside, California, and was formed to develop, research, and promote innovative muti-pharmacophore therapies. To learn more about CTZ1™ as a therapeutic agent for the treatment of Age-Related Macular Degeneration, visit our website here: citrustherapeutics.com
Citrus Therapeutics is also considered for the 2022 Ophthalmology Innovator Award for CTZ1™.
CTZ1™ is a unique vascular disruptive agent for combating the oxidative damage encountered in macular degeneration. CTZ1™ combines an antioxidant moiety fused to an angiogenic-modulating activity structure; consequently, this multi-pharmacophore combination mitigates oxidant damage experienced in AMD. CTZ1™ - as a "vascular disruptive agent" - can stabilize and temper pathological angiogenic processes secondary to progressive AMD.
More on The Californer
- Mountzo Launches TV Mounting in Sacramento, Expanding Nationwide
- Thursday's Hair Solutions Announces Online Booking Option to Schedule Free Consultations
- Gallagher Domanski PLC Announces Multiple Recent EB-2 NIW Approvals Across STEM & Infrastructure
- Keep Your Eyes To The Sky…We Up !
- Trade Course Hub Expands Online Library of Trading Courses and Education
CTZ1™ is currently being developed with potential as a topical (i.e., eye drop solution) and local (i.e., intravitreal) therapy.
CTZ1™ makes its debut from Citrus Therapeutics, LLC, based out of Riverside, California. Citrus Therapeutics is owned and operated by Eric Chin MD, David Almeida MD MBA PhD, and Mr. Ahmad Alkayali, inventor.
For more information about CTZ1™ and its applications email salkayali@citrustherapeutics.com
About Citrus Therapeutics
Citrus Therapeutics, LLC is a U.S. company based in Riverside, California, and was formed to develop, research, and promote innovative muti-pharmacophore therapies. To learn more about CTZ1™ as a therapeutic agent for the treatment of Age-Related Macular Degeneration, visit our website here: citrustherapeutics.com
Source: Citrus Therapeutics
Filed Under: Medical
0 Comments
Latest on The Californer
- California: Governor Newsom signs bill strengthening local journalism, defending a free press as cornerstone of democracy
- Long Beach: Community Invited to Attend No-Cost Waste Reduction & Recycling Workshops in English and Spanish from October 2026 through August 2027
- Rabies-Positive Bat Confirmed in Long Beach
- City of Long Beach Issues Extreme Heat Alert, Advises Residents to Take Precautions Against Heat
- Fiscal Year 2027 Begins; City of Long Beach Provides Update on Efforts to Address Staffing Impacts
- City of Long Beach Awards $205,000 to Level Up Small Businesses
- Long Beach: Community Invited to Celebrate Reopening of the Newly Renovated Drake Park Community Center
- Los Angeles County Will Begin Mailing Vote by Mail Ballots to Registered Voters in the City of Long Beach Beginning Oct. 1, 2026
- City of Long Beach Launches Third Cohort of the Urban Planning and Design Internship Program
- Long Beach Public Library Announces 2027 Youth Poet Laureate Program
- Build a Distinctive Brand Identity That Connects With Customers
- MVP Advances Semiconductor Inspection with AOI, Metrology & AI at SEMICON West 2026
- Great Awakening Report Continues Independent Research on Truth, Awakening, and Disclosure
- Community Colleges of Ventura County to Host State of the District Event
- Ventura College to Host Cash for College Workshops in October
- PQCrypto Welcomes Technology Executive John Basmadjian to Board of Directors
- GIC Car Clinic Joins Brakes for Breasts With Free Brake Checks and Free Pad
- MyMediaGuy Search Launches to Help Local Businesses Get Found on Google Maps, Search and AI
- CardsNearby Launches Free Nationwide Directory of Card Shows and Local Card Shops for Collectors
- How Are Ai Founders in Silicon Valley Building Startups in Their Sleep?